In Silico Target Assessment Services

Target identification and validation is one of the biggest challenges in the pharmaceutical industry, with many promising treatments failing in the clinic due to efficacy or target-related safety issues. The reason is usually that the underlying hypothesis turns out to be wrong, or there are unwanted consequences of modulating the target. Due diligence around a target early on, can make the difference between success and failure of a program.

In this video, Dr. Kenneth Barr, Syngene's Sr. Vice President of Discovery Services, answers some of the frequently asked questions about Syngene’s in-silico target assessment services. Syngene specialize in in silico-based identification, selection, analysis, and prioritization of potential drug targets by using a combinatorial approach of biology and bioinformatics.